MethylGene Inc. (TSX:MYG) is a publicly-traded, clinical stage, biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer. The Company's product candidates include:

• MGCD265,  an oral, multi-targeted kinase inhibitor targeting the c-Met, VEGF1, VEGF2, VEGF3, Ron and Tie-2 receptor tyrosine kinases. MGCD265 is in a Phase II program for solid tumor cancers and NSCLC;
• MGCD0103, an oral, isotype-selective histone deacetylase inhibitor which has been in multiple clinical trials for solid tumors and hematological malignancies and is licensed to Taiho Pharmaceutical;
• MGCD290, a fungal Hos2 inhibitor used in combination with azoles for fungal infections. This compound is in Phase I clinical studies in healthy volunteers.

MethylGene's development and commercialization partners include Taiho Pharmaceutical, Otsuka Pharmaceutical and EnVivo Pharmaceuticals.

MethylGene develops drugs that specifically target enzymes that are involved in certain diseases such as cancer. We do this by understanding the characteristics of the enzyme involved in the disease and then creating a molecule that will specifically inhibit that enzyme from functioning. In this way, the enzyme may be controlled. Once we have a set of lead molecules, we have a seasoned biology team to then test our candidate drugs. Molecules that have the desired profile become clinical candidates and are eventually tested in human clinical trials.

The advantage of having drugs that are specific to their target is that they should only affect diseased cells leaving healthy cells untouched. This is in contrast to other approaches such as chemotherapy or radiation therapy where both healthy and diseased cells are affected causing unnecessary side effects.

Our strength is in our ability to discover, to develop, and deliver target-specific drugs. We invite you to browse our web site to learn more about MethylGene.